Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...
(UroToday.com) The 2026 ASCO annual meeting featured a bladder cancer rapid abstract session and a presentation by Dr. Emanuele Crupi discussing a phase II study of ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a session on new approaches to curing bladder and kidney cancer. Dr. Peter O'Donnell presented ...
(UroToday.com) The 2026 PSMA & Beyond conference featured a clinical trial updates session and presentation by Dr. Désirée Deandreis discussing the PEACE-6 PR trial. Recently, prostate cancer is ...
(UroToday.com) The 2025 SUO annual meeting featured a kidney session and a presentation by Dr. Brian Shuch discussing ZIRCON-X and the impact of 89 Zr-girentuximab PET/CT versus conventional imaging ...
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Arun Azad discussing EvoPAR-Prostate01, a phase III, double-blind, ...
(UroToday.com) The 2024 American Urological Association (AUA) annual meeting featured a plenary session, and a presentation by Dr. Todd Morgan discussing the AUA guidelines for salvage therapy for ...
ASCO 2024 Bladder Cancer ASCO 2024: What Is Variant Histology Urothelial Cancer and What Are the Available Treatment Options? ASCO 2024: Phase II Trial of Intravesical Camrelizumab in BCG-Unresponsive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results